Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study

BACKGROUND: Apremilast, an oral phosphodiesterase‐4 inhibitor, has demonstrated efficacy in patients with moderate to severe psoriasis. OBJECTIVE: To evaluate long‐term efficacy and safety of apremilast in biologic‐naive patients with moderate to severe plaque psoriasis and safety of switching from...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Eur Acad Dermatol Venereol
Main Authors: Reich, K., Gooderham, M., Bewley, A., Green, L., Soung, J., Petric, R., Marcsisin, J., Cirulli, J., Chen, R., Piguet, V.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles and Short Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5873268/
https://ncbi.nlm.nih.gov/pubmed/29220542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.14738
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares